earnings
confidence high
sentiment neutral
materiality 0.60
Amneal Q3 net revenue up 13% to $702M; adjusted EBITDA $158M, guidance affirmed
Amneal Pharmaceuticals, Inc.
2024-Q3 EPS reported
-$0.28
revenue$2,063,439,000
- Net revenue $702M (+13% YoY); GAAP net loss ~$0.2M vs prior year net income of $10M.
- Adjusted EBITDA $158M (+2% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.
- Generics +9%, Specialty +19% driven by CREXONT/ONGENTYS launches; AvKARE +21%.
- Affirms full-year 2024 guidance; launched CREXONT, collaboration with Metsera, in-licensed biosimilar.
- Higher interest expense drove GAAP net loss and lower adjusted EPS.